Omniome raises $60M series B
DNA sequencing company Omniome Inc. (San Diego, Calif.) raised $60 million on July 30 in a series B round led by new investors Decheng Capital and Hillhouse Capital Group. New investors Lam Research Capital and Nan Fung Life Sciences also participated, as did existing investors Arch Venture Partners, Domain Associates, Biomatics Capital Partners and Altitude Life Science Ventures.
Omniome is developing its Sequencing by Binding DNA sequencing technology. According to the company, the technology relies on the natural binding event between nucleotides and polymerases to analyze DNA sequencing and has potential applications in single-cell sequencing, clinical sequencing and cancer diagnostics. Omniome said the funds will be used to hire additional employees to help optimize its technology and develop prototypes of commercial sequencing platforms...